Results 201 to 210 of about 14,060,785 (382)

The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
E. Plowman, Lauren C. Tabor, J. Wymer, Gary L. Pattee   +3 more
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Changes of Clinical Practice Patterns of Allergen Immunotherapy in Korea. [PDF]

Allergy Asthma Immunol Res
Lee HY, Kang SY, Kim K, Kim JH, Ryu G, Min JY, Park KH, Park SY, Sung M, Lee Y, Yang EA, Jee HM, Ha EK, Shin YS, Lee YW, Chung EH, Choi SH, Koh YI, Kim ST, Nahm DH, Park JW, Shim JY, Han DH, Han MY, Lee SM, Choi JH, Korean Academy of Asthma Allergy and Clinical Immunology (KAAACI) working group on Allergen Immunotherapy and Allergen.   +26 more
europepmc   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

Architectural Patterns in Practice [PDF]

, 2005
Avgeriou, Paris, Zdun, Uwe
core  

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

Trends in Practice Patterns and Clinical Outcomes for Desmoid Tumors: A Large Single-Institutional Australian Cohort. [PDF]

Cancer Med
Sia J, Tan S, Mohanakrishnan N, Yu K, Ngan SY, Chander S, Desai J, Lewin J, Hamilton A, Luen SJ, Gyorki DE, Snow H, DiBella C, O'Reilly-Harbidge S, Orme LM, Chu J, Bae S.   +16 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Practice patterns and percutaneous coronary intervention outcomes: a comparison between Sweden and the US. [PDF]

Eur Heart J Open
Sampath-Kumar R, Mohammad M, von Koch S, Reeves R, Al Khiami B, Ang L, Melendez A, Mahmud E, Ben-Yehuda O, Erlinge D.   +9 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source